[1] |
McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density[J]. N Engl J Med, 2014, 370(5):412-420.
|
[2] |
Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2014, 25(10):2359-2381.
|
[3] |
Deal CL. Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons[J]. Curr Rheumatol Rep, 2001, 3(3):233-239.
|
[4] |
邱贵兴,裴福兴,胡侦明.中国骨质疏松性骨折诊疗指南(骨质疏松性骨折诊断及治疗原则)[J]. 中华骨与关节外科杂志,2015,8(5):371-374.
|
[5] |
尤瑞金,杨德育,吕宏升,等.椎体强化术后邻近椎体再骨折的治疗[J].中国矫形外科杂志,2016,24(14):1274-1277.
|
[6] |
左薇,费琦,杨雍,等.BMD、OSTA与FRAX预测绝经后女性骨质疏松性骨折风险的比较研究[J].中国骨质疏松杂志,2015,21(1):48-52.
|
[7] |
Yoo CM, Park KB, Hwang SH, et al. The analysis of patterns and risk factors of newly developed vertebral compression fractures after percutaneous vertebra plasty[J]. J Korean Neurosurg Soc, 2012, 52(4):339-345.
|
[8] |
Chen WJ, Kao YH, Yang SC, et al. Impact of cement leakage into disks on the development of adjacent vertebral compression fractures[J]. J Spinal Disord Tech, 2010, 23(1):35-39.
|
[9] |
Mudano AS, Bian J, Cope JU, et al. Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study[J]. Osteoporos Int, 2009, 20(5):819-826.
|
[10] |
Zou J, Mei X, Zhn X, et al. The long-term incidence of subsequent vertebral body fracture after vertebral augmentation therapy: a systemic review and meta-analysis[J]. Pain Physician, 2012, 15(4):E515-522.
|
[11] |
Han SL, Wan SL, Li QT, er al. Is vertebroplasty a risk factor for subsequent vertebral fracture, meta-analysis of published evidence[J]. Osteoporos Int, 2015, 26(1):113-122.
|
[12] |
张萌萌.中国老年学学会骨质疏松委员会骨代谢生化指标临床应用专家共识[J].中国骨质疏松杂志,2014,20(11):1263-1272.
|
[13] |
王娟,张川江,刘敏,等.育龄期女性骨代谢与碘摄入过量及甲状腺功能亢进之间的关系研究[J].标记免疫分析与临床,2017,24(5):530-533.
|
[14] |
Vasikaran SD, Chubb SP, Ebeling PR, et al. Harmonised Australian reference intervals for serum PINP and CTX in adults[J]. Clin Biochem, 2014, 35(4):237-242.
|
[15] |
Vasikaran S, Cooper C. International Osteoporosis Foundation and International Federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis[J]. Clin Chem Lab Med, 2011, 49(8):1271.
|
[16] |
Sun T, Chen M, Lin X, et al. The influence of osteoprotetin genetic polymorphisms on bone mineral density and osteoporosis in Chinese postmenopausal women[J]. Int Immunopharmacol, 2014, 22(1):200-203.
|
[17] |
遇呈祥,陈亮,宴铮剑,等.骨密度对骨质疏松性骨折的判断价值[J].中国骨质疏松杂志,2012,18(2):127-129.
|
[18] |
Veitch SW, Findlay SC, Hamer AJ, et al. Changes in bone mass and bone turnover following tibial shaft fracture[J]. Osteoporos Int, 2006, 17(3):364-372.
|
[19] |
陈森雄,唐荣德,华关民,等.血淸骨标志物在骨质疏松症等5种疾病中的表达[J].检验医学与临床,2017,14(3):431-433.
|